This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon Announces Second Quarter 2012 Results

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of approximately 1500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full prescribing information at or call 1-877-336-3736.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding the expected benefits of the restructuring, the timing and elements of the restructuring, the timing and form of related charges, the expected annual operating expense reduction, and Dendreon’s ability to achieve improved performance as a result of the restructuring, developments affecting Dendreon's business and prospects and potential revenue and earnings from product sales, and progress generally on commercialization efforts for PROVENGE. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Dendreon’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, our inability to achieve and sustain commercial success for PROVENGE; the identification of efficacy, safety or other issues with PROVENGE; a slower than anticipated adoption by treating physicians of PROVENGE for the treatment of patients with advanced prostate cancer due to competing therapies, perceived difficulties in the treatment process, delays in obtaining reimbursement or for other reasons; any promotional limitations imposed by the FDA on our ability to commercialize and market PROVENGE; unexpected difficulties and costs associated with the rapid expansion of our operations to support the commercial launch of PROVENGE; and other factors discussed in the “Risk Factors” section of Dendreon’s Annual Report on Form 10-K for the year ended December 31, 2011. All forward-looking statements are qualified in their entirety by this cautionary statement. Dendreon is providing this information as of the date of this release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
(in thousands, except per share amounts)
Three Months EndedJune 30, Six Months EndedJune 30,
2012   2011   2012   2011  
(unaudited) (unaudited)
Product revenue, net $ 79,964 $ 48,139 $ 161,936 $ 75,140
Royalty and other revenue   28     20     130     41  
Total revenue 79,992 48,159 162,066 75,181
Operating expenses:
Cost of product revenue 61,731 28,754 121,772 47,092
Research and development 19,697 18,565 37,040 36,174
Selling, general and administrative 80,219 105,071 175,534 200,360
Restructuring   1,099         975      
Total operating expenses   162,746     152,390     335,321     283,626  
Loss from operations (82,754 ) (104,231 ) (173,255 ) (208,445 )
Interest income 375 393 758 793
Interest expense (13,768 ) (12,121 ) (27,580 ) (21,114 )
Other income (expense)   10     (26 )   26     (26 )
Net loss $ (96,137 ) $ (115,985 ) $ (200,051 ) $ (228,792 )
Basic and diluted net loss per share $ (0.65 ) $ (0.79 ) $ (1.35 ) $ (1.57 )


Shares used in computation of basic and diluted net loss per share
  148,161     145,928     147,880     145,712  
June 30, December 31,

Balance Sheet Data:
Cash and cash equivalents $ 247,493 $ 427,100
Short-term investments 184,743 111,525
Long-term investments 77,479 79,071
Trade accounts receivable 35,343 35,541
Prepaid antigen costs 1,534 7,490
Inventory 71,558 69,502
Total assets 875,747 1,001,491
Convertible senior notes due 2016 520,335 508,418
Convertible senior subordinated notes due 2014 27,685 27,685
Total stockholders' equity 202,409 352,637
(in thousands, except per share amounts)
Three Months EndedJune 30, Six Months EndedJune 30,
2012   2011   2012   2011  
(unaudited) (unaudited)
GAAP net loss $ (96,137 ) $ (115,985 ) $ (200,051 ) $ (228,792 )
Non-GAAP adjustments:
Depreciation and amortization expense 10,790 8,644 21,654 15,955
Imputed interest related to the convertiblesenior notes due 2016 6,019 5,551 11,917 9,851
Restructuring 1,099 975
Management severance and othertermination benefits:
Severance expense 1,792 6,965
Non-cash stock-based compensation expense 3,434 15,112
Other stock-based compensation expense   12,793     16,754     32,268     31,430  
Non-GAAP net loss $ (60,210 ) $ (85,036 ) $ (111,160 ) $ (171,556 )
Non-GAAP net loss per share- basic and diluted $ (0.41 ) $ (0.58 ) $ (0.75 ) $ (1.18 )


Shares used in computation of basic and diluted net loss per share
  148,161     145,928     147,880     145,712  

The above table provides certain non-GAAP financial measures that include adjustments to GAAP figures. Dendreon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Dendreon's financial performance and its prospects for the future. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of operational results and trends. We believe excluding these items provides important insight into our operational results, important for a company at our stage in development. In addition, these non-GAAP financial measures are among the indicators Dendreon management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP figures.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.01 -2.70%
FB $104.02 -5.90%
GOOG $684.00 -3.40%
TSLA $163.01 -7.00%
YHOO $27.97 -4.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs